Lupin gains USFDA nod for Raltegravir Tablets USP, 600 mg EP News Bureau May 9, 2025 Being the exclusive first-to-file, Lupin is eligible for 180-day generic exclusivity
Lupin receives tentative U.S. FDA approval for Raltegravir tablets EP News Bureau Nov 11, 2024 Lupin may secure 180-day exclusivity to market a generic version of Merck’s Isentress HD
